The funding round was led by Montage Ventures with participation from Laidlaw Scholars Ventures, Apex Ventures, and Continuum Health Ventures. Joining as individual investors are industry leaders Dr. Maximilien Levesque, CEO & Co-Founder of Aqemia, and Naheed Kurji, former President of Recursion Pharmaceuticals Canada and CEO & Founder of Cyclica.
CardiaTec, a spin-out from the Han Lab at the University of Cambridge, employs computational methods to decode the biology behind cardiovascular disease. was co-founded by Raphael Peralta (CEO and Laidlaw Scholar alumnus), Thelma Zablocki (COO), and Prof. Namshik Han (CTO).
Raphael Peralta, CEO & Co-Founder, commented on the milestone:
Modelling complex cardiovascular disease biology across multiple omic dimensions has immense potential in unlocking new therapeutic strategies that will challenge the current standard of care. Over the last several years, I am proud of the relentless drive of the team in reaching important milestones and our collective ambition towards tackling a tough global problem. I look forward to working with our investors to accelerate our development
Prof. Namshik Han, CTO & Co-Founder, followed up:
Building on several years of research and the success of research collaborations between my lab and BioPharma companies, we are excited about the pioneering work we are doing at CardiaTec. By leveraging deep human heart phenotyping and state-of-the-art computational modelling, we aim to discover transformative therapeutics.